Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: topline results from a ...

Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...

Older adults face unique barriers in hypertension management, including comorbidities, mobility limitations, and medication adherence challenges, impacting digital health tool effectiveness. Trials ...

Based on findings from her study, "Pricing and Insurance Networks in Outpatient Surgery Markets," lead investigator Xiaoxi Zhao, PhD, recommends aligning patient and insurer incentives to encourage ...

The introduction of more stringent work requirements for those enrolling or renewing their Medicaid coverage can affect both children and adults. The One Big Beautiful Bill Act (OBBBA) introduced a ...

Panelists discuss how accurate and early diagnosis remains one of the most difficult challenges in schizophrenia care. Many ...

The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

Panelists discuss how genetic predisposition is a major determinant in schizophrenia risk, with heritability playing a ...

A new option is now approved to treat adults living with high-risk smoldering multiple myeloma (MM). 1 The FDA has greenlit ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to ...

Panelists discuss how pharmacy-driven barriers, including delayed statin initiation and failure to escalate therapy, ...